SYnAbs S.A. of Gosselies at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

SYnAbs S.A.

48 rue Auguste Piccard, 6041 Gosselies
Belgium
Telephone +32 71 374880
Fax +32 71 374880
isoardj@synabs.be

This company is co-exhibitor of
AWEX - Wallonia Export & Investment

Hall map

MEDICA 2019 hall map (Hall 1): stand F53

Fairground map

MEDICA 2019 fairground map: Hall 1

Our products

Product category: Other diagnostics

MYstik™, plug&play mouse isotyping kit

SYnAbs Mouse Immunoglobulin Easy Isotyping Kit or a.k.a. "MYstik™" provides a rapid and easy method (DOT technology) to characterize mouse monoclonal antibody isotypes in cell culture supernatants or purified antibodies preparations. This Plug&Play kit includes ready-to-use reagents necessary to analyze 24 samples in less than 1h30. Buffer solutions are color coded in order to simplify pipetting steps.

The method is based upon robust EIA enzyme immunoassay technique:  SYnAbs unique rat anti-mouse monoclonals are highly specific to each of the common light and heavy chains of mouse species and can discrimate between IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, IgE, kappa chain and lambda chain. Samples are placed on the strip without any predilution. If desired isotype mAb is present, it will bind to rat mAb by affinity. Note that only specific mAb and none the irrelevant molecules will bind. That counts for the specificity of the test. Second mAb is then added, this one conjugated with enzyme. Colorgenic enzyme substrate is added. The interaction between substrate and captured enzyme generates visible color or dot.

More Less

Product category: Other diagnostics

SYnAbs residual protein A test

Staphylococcus aureus protein A is a 42 kDa cell wall constituent characterized by its binding capacity to the Fc portion of immunoglobulins. Protein A resins is commonly used to purify monoclonal antibodies as a robust capture step during Down-Stream Processing.

 

Traditional residual protein A test are ELISA which can detect the total amount of residual protein A. Detaching buffer is often necessary because the proposed ELISAs are unable to recognize protein linked to the mAb of interest. However, the mentioned buffer may interfere in a sandwich ELISA assay, and it is not proved that the purified monoclonal antibody is completely detached.

Facing the hurdle, SYnAbs has developed the first rat mAb ables to distinguish free protein A  from protein A linked to immunoglobulins with a 0,5 ng/ml sensitivity.

More Less

Product category: Other diagnostics

SYnAbs, immunoaffinity chromatography purification

Immunoaffinity chromatography a.k.a. IAC is a type of chromatography in which the stationary phase is composed with an antibody. This technique represents a special sub category of affinity chromatography in which a biological agent is used for its strong and specific binding capacities to a target compound.

SYnAbs routinely used immunoaffinity columns for the purification of its mouse and rats off-the-shelf monoclonal antibodies and has decided to offer to its customers the possibility to bind SYnAbs antibodies or your custom monoclonal antibody to the resin of your choice.

More Less

Product category: Other diagnostics

Anti-His tag monoclonal antibodies (mAbs)

A poly-histidine tag is an amino acid motif in consisting of several histidine residues, inserted either at the N- or C-terminus of the protein. It is frequently used for

  • purification by IMAC affinity chromatography of proteins produced in E.Coli expression system, 
  • protein-protein interactions,
  • fluorescent dyes to follow the circulation of specific proteins.
SYnAbs developed a rat monoclonal antibody targeting N-terminal and C-terminal parts of your histidine tag with strong specificity.

More Less

About us

Company details

SYnAbs' vision is to fill the gap on the marketplace for innovative mAbs against poor immunogenic compounds and complex antigens. Targeting steroids, peptides, small molecules, toxins, lipids and polysaccharides (on fungi and bacteria), SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat and guinea pig species to generate unique monoclonal antibodies of extreme specificity and higher affinity.

SYnAbs was set up in September 2015 out of Professor Pierre Gianello’s experimental surgery laboratory (CHEX) in order to develop greater expertise in the custom production of monoclonal antibodies, of rats but also of guinea pigs. The UCL spin-off was set up as a result of coordinated action by the laboratory, the Louvain Technology Transfer Office (LTTO), Wallonia Biotech Coaching and a French group, Biotech Investissement (which owns RD Biotech and Diaclone companies).

The equity investment by Biotech Investissement (based in Besançon, France) was decisive in validating the business plan. This group provides services to biopharmaceutical companies and produces custom monoclonal antibodies. The complementary nature of the two entities, SYnAbs and Biotech Investissement, will make it possible to consolidate SYnAbs’s activity in Belgium and to expand its sales network in France and the Netherlands. This partnership, the key element in setting up the spin-off, was also possible thanks to the partnership between the LTTO and Wallonia Biotech Coaching (WBC), the incubator for life sciences in Wallonia. Thanks to WBC, the SYnAbs project has benefited from the CxO measure for «orphan» projects which meant that a business mentor could be recruited for the final phases of setting up the company. The work by Didier Argentin, the business mentor assigned by WBC to SYnAbs and now the CEO of the spin-off, was decisive in establishing the collaboration with Biotech Investissement.

SYnAbs SA is currently involved in the production of rat monoclonal antibodies, serving CROs (mAb and custom immunoassays) and with a large catalogue of secondary monoclonal antibodies (more than a hundred secondary anti-immunoglobulins) and unique primary monoclonal antibodies has gained strong international recognition which its founders wish to increase further.

Thanks to its scientists led by their CSO Yannick Nizet, PhD, as well as the broad biotechnology support offered by its sister companies Rd-Biotech and Diaclone, France, SynAbs can indeed present a one-stop-shop portfolio of services, covering the antigen synthesis and the hapten-carriers chemistry, through the parallel immunisation of mice, rats and guinea pigs, up to the custom generation and manufacturing of gram levels of these mouse, rat and guinea pigs monoclonal antibodies.

This unique triple immunisation platform enables SynAbs to increase the probability getting the unique monoclonal you’re looking for, and therefore maximizes the success rate of
our clients !
SynAbs has currently 130 m2 of production laboratories and generates earnings of 1 million euro.
Discover our first press release in English, French and Dutch.

More Less